3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Pancreatic Neoplasms
47
Carcinoma, Non-Small-Cell Lung
14
Neoplasm Metastasis
11
Neoplasms
9
Colorectal Neoplasms
8
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Lung Neoplasms
6
Sarcoma
5
Melanoma
4
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Pancreatic Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
TNBC
1
Solid Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
Dexamethasone
33
Cyclophosphamide
31
fludarabine
19
venetoclax
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT02075021
2018-10-15
rev/abraxane
NYU Langone Health
Phase 1/2
Terminated
3 enrolled
3 charts